Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein

Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are characterized by the aberrant accumulation of intracytoplasmic misfolded and aggregated α-synuclein (α-Syn), resulting in neurodegeneration associated with inflammation. The propagation of α-Syn aggregates from cell to cell is implicated in the spreading of pathological α-Syn in the brain and disease progression. We and others demonstrated that antibodies generated after active and passive vaccinations could inhibit the propagation of pathological α-Syn in the extracellular space and prevent/inhibit disease/s in the relevant animal models. We recently tested the immunogenicity and efficacy of four DNA vaccines on the basis of the universal MultiTEP platform technology in the DLB/PD mouse model. The antibodies generated by these vaccines efficiently reduced/inhibited the accumulation of pathological α-Syn in the different brain regions and improved the motor deficit of immunized female mice. The most immunogenic and preclinically effective vaccine, PV-1950D, targeting three B-cell epitopes of pathological α-Syn simultaneously, has been selected for future IND-enabling studies. However, to ensure therapeutically potent concentrations of α-Syn antibodies in the periphery of the vaccinated elderly, we developed a recombinant protein-based MultiTEP vaccine, PV-1950R/A, and tested its immunogenicity in young and aged D-line mice. Antibody responses induced by immunizations with the PV-1950R/A vaccine and its homologous DNA counterpart, PV-1950D, in a mouse model of PD/DLB have been compared.

[1]  E. Masliah,et al.  Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies , 2022, npj Vaccines.

[2]  F. Rahbarizadeh,et al.  A brief review on DNA vaccines in the era of COVID-19 , 2021, Future virology.

[3]  H. Chandra,et al.  Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India , 2021, EClinicalMedicine.

[4]  S. Biswas,et al.  Methods to improve the immunogenicity of plasmid DNA vaccines. , 2021, Drug discovery today.

[5]  R. Koh,et al.  Immunotherapies for Parkinson's disease: Progression of Clinical Development. , 2021, CNS & neurological disorders drug targets.

[6]  L. Ferrucci,et al.  Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.

[7]  C. Gravel,et al.  Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions , 2020, Journal of Parkinson's disease.

[8]  S. Silvestre,et al.  Alzheimer's disease: Recent treatment strategies. , 2020, European journal of pharmacology.

[9]  D. Weissman,et al.  Recent advances in mRNA vaccine technology. , 2020, Current opinion in immunology.

[10]  A. Obenaus,et al.  Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials , 2020, Neurobiology of Disease.

[11]  N. Petrovsky,et al.  Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice , 2019, Alzheimer's Research & Therapy.

[12]  N. Petrovsky,et al.  A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice , 2019, Scientific Reports.

[13]  J. Cedarbaum,et al.  Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 , 2019, Movement disorders : official journal of the Movement Disorder Society.

[14]  H. Nielsen,et al.  α-synuclein in the pathophysiology of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[15]  Margaret A. Liu A Comparison of Plasmid DNA and mRNA as Vaccine Technologies , 2019, Vaccines.

[16]  T. Roberts,et al.  Genetics, Human Major Histocompatibility Complex (MHC) , 2019 .

[17]  O. Iordache,et al.  Technologies , 2018, Studies in Systems, Decision and Control.

[18]  E. Masliah,et al.  MultiTEP platform–based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency , 2017, Neurobiology of Aging.

[19]  P. Offit,et al.  Plotkin's Vaccines , 2017 .

[20]  D. Cribbs,et al.  MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. , 2017, Vaccine.

[21]  D. Cribbs,et al.  Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  M. Grundman,et al.  First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[23]  N. Petrovsky,et al.  Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules , 2016, Scientific Reports.

[24]  Even Fossum,et al.  Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines , 2015, Front. Immunol..

[25]  Mary M. Cavanagh,et al.  Naive T Cell Maintenance and Function in Human Aging , 2015, The Journal of Immunology.

[26]  J. Trojanowski,et al.  α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration , 2014, Cell reports.

[27]  D. Cribbs,et al.  The MultiTEP platform–based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates , 2014, Alzheimer's & Dementia.

[28]  D. Cribbs,et al.  Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques , 2014, Alzheimer's & Dementia.

[29]  D. Cribbs,et al.  Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: Feasibility study , 2014, Neuroscience Letters.

[30]  Susan Lindquist,et al.  Mechanisms of protein-folding diseases at a glance , 2014, Disease Models & Mechanisms.

[31]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[32]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[33]  A. Kiyatkin,et al.  Refinement of a DNA based Alzheimer disease epitope vaccine in rabbits , 2013, Human vaccines & immunotherapeutics.

[34]  E. Masliah,et al.  Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.

[35]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[36]  E. Sigurdsson,et al.  Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.

[37]  E. Masliah,et al.  Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.

[38]  J. Julien,et al.  Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS , 2010, Journal of neurochemistry.

[39]  D. Cribbs,et al.  DNA prime–protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type mice , 2010, Gene Therapy.

[40]  G. Pawelec,et al.  Immunity, ageing and cancer , 2008, Immunity & Ageing.

[41]  P. Mcgeer,et al.  The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease , 2008, Experimental Neurology.

[42]  J. Marsh,et al.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Montefiori,et al.  Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting , 1998, Journal of Virology.

[44]  R. Coffman,et al.  Lymphokine control of in vivo immunoglobulin isotype selection. , 1990, Annual review of immunology.

[45]  R. Coffman,et al.  Heterogeneity of cytokine secretion patterns and functions of helper T cells. , 1989, Advances in immunology.

[46]  R. Fernandez-Botran,et al.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells , 1988, Nature.

[47]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[48]  K. Welsh,et al.  The human major histocompatibility complex (MHC) , 1984 .

[49]  D. Penn,et al.  The major histocompatibility complex (MHC). , 1983, Transplantation proceedings.